Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 20/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1820742 | 1.00 | CHRM3 (0.77) | CHRM3 | |
| Hydrochloric Acid SCHEMBL1820572 | 1.00 | CHRM3 (0.77) | CHRM3 | |
| SCHEMBL524890 | 1.00 | CHRM3 (0.77) | CHRM3 | |
| Bromide SCHEMBL524472 | 0.99 | CHRM3 (0.75) | CHRM3 | |
| Bromide SCHEMBL524473 | 0.99 | CHRM3 (0.75) | CHRM3 | |
| Hydrochloric Acid SCHEMBL2189973 | 0.91 | CHRM3 (0.64) | CHRM3 | |
| Hydrochloric Acid SCHEMBL2189969 | 0.91 | CHRM3 (0.64) | CHRM3 | |
| SCHEMBL1822645 | 0.91 | CHRM3 (0.64) | CHRM3 | |
| SCHEMBL10147698 | 0.91 | CHRM3 (0.64) | CHRM3 | |
| Hydrochloric Acid SCHEMBL1432027 | 0.91 | CHRM3 (0.75) | CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150141387-A1 | PHARMACEUTICAL PRODUCT COMPRISING A P38 KINASE INHIBITOR AND A SECOND ACTIVE INGREDIENT | ASTRAZENECA UK LIMITED (GB) | 2015-05-21 | — | — | US | claimed |
| US-20120028941-A1 | Pharmaceutical Product Comprising a P38 Kinase Inhibitor and a Second Active Ingredient | ASTRAZENECA UK LIMITED (GB) | 2012-02-02 | — | — | US | claimed |
| EP-2379174-A1 | PHARMACEUTICAL PRODUCT COMPRISING A P38 KINASE INHIBITOR AND A SECOND ACTIVE INGREDIENT | AstraZeneca AB (SE) | 2011-10-26 | — | — | EP | claimed |
| US-20100261690-A1 | NOVEL COMBINATIONS | ASTRAZENECA R&D (SE) | 2010-10-14 | — | — | US | claimed |
| WO-2010071583-A1 | PHARMACEUTICAL PRODUCT COMPRISING A P38 KINASE INHIBITOR AND A SECOND ACTIVE INGREDIENT | ASTRAZENECA AB (SE) | 2010-06-24 | — | — | WO | claimed |
| WO-2010008341-A1 | A COMBINATION OF (A) GLUCOCORTICOID RECEPTOR MODULATOR AND (B) A MUSCARINIC ANTAGONIST | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | WO | claimed |
| US-10954211-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2021-03-23 | — | — | US | disclosed |
| US-20190330187-A1 | Chemical Compounds | ASTRAZENECA UK LIMITED (GB) | 2019-10-31 | — | — | US | disclosed |
| EP-3119752-B1 | 3,4-DIAMINO-6-CHLOROPYRAZINE-2-CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF ENAC MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2018-05-16 | — | — | EP | disclosed |
| US-20150141387-A1 | PHARMACEUTICAL PRODUCT COMPRISING A P38 KINASE INHIBITOR AND A SECOND ACTIVE INGREDIENT | ASTRAZENECA UK LIMITED (GB) | 2015-05-21 | — | — | US | disclosed |
| US-8969350-B2 | Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient | ASTRAZENECA AB (SE) | 2015-03-03 | — | — | US | disclosed |
| EP-2624838-A1 | NOVEL COMBINATIONS | AstraZeneca AB (SE) | 2013-08-14 | — | — | EP | disclosed |
| US-20120269872-A1 | NOVEL SALT 628 | ASTRAZENECA AB (SE) | 2012-10-25 | — | — | US | disclosed |
| WO-2011073662-A1 | COMBINATION OF A BENZOXAZINONE AND A FURTHER AGENT FOR TREATING RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2011-06-23 | — | — | WO | disclosed |
| US-20100261690-A1 | NOVEL COMBINATIONS | ASTRAZENECA R&D (SE) | 2010-10-14 | — | — | US | disclosed |
| US-20100261690-A1 | NOVEL COMBINATIONS | ASTRAZENECA R&D (SE) | 2010-10-14 | — | — | US | disclosed |
| WO-2010114472-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A STEROIDAL[3,2-C]PYRAZOLE DERIVATIVE AND A SECOND PHARMACEUTICALLY ACTIVE COMPOUND | ASTRAZENECA AB (SE) | 2010-10-07 | — | — | WO | disclosed |
| US-20100216843-A1 | NOVEL SALT 628 | ASTRAZENECA R&D | 2010-08-26 | — | — | US | disclosed |
| WO-2010071583-A1 | PHARMACEUTICAL PRODUCT COMPRISING A P38 KINASE INHIBITOR AND A SECOND ACTIVE INGREDIENT | ASTRAZENECA AB (SE) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010008341-A1 | A COMBINATION OF (A) GLUCOCORTICOID RECEPTOR MODULATOR AND (B) A MUSCARINIC ANTAGONIST | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261690-A1 | NOVEL COMBINATIONS | ADRB2, NR3C2, GRK4 | CHRM3 21/4885 |
| US-10954211-B2 | Chemical compounds | CFTR, SCNN1B, SCNN1A | CHRM3 167/4885 |
| US-20150141387-A1 | PHARMACEUTICAL PRODUCT COMPRISING A P38 KINASE INHIBITOR AND A SECOND ACTIVE INGREDIENT | NR3C2, GRK4, PTGER2 | CHRM3 629/4885 |
| US-20120269872-A1 | NOVEL SALT 628 | REN, SCN8A, SLC38A7 | CHRM3 2502/4885 |
| US-20100216843-A1 | NOVEL SALT 628 | REN, SCN8A, SLC38A7 | CHRM3 3143/4885 |
| US-20190330187-A1 | Chemical Compounds | CFTR, SCNN1B, SCNN1A | CHRM3 167/4885 |
| US-20120028941-A1 | Pharmaceutical Product Comprising a P38 Kinase Inhibitor and a Second Active Ingredient | NR3C2, ARRB1, GRK4 | CHRM3 654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.